

Clinical Trial Central Laboratory Services Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Service, By Indication, By End-use, By Region, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/CE730A8255E2EN.html>

Date: March 2025

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: CE730A8255E2EN

Abstracts

This report can be delivered to the clients within 2 Business Days

Clinical Trial Central Laboratory Services Market Growth & Trends

The global clinical trial central laboratory services market size is expected to reach USD 6.97 billion by 2030, growing at a CAGR of 9.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing number of clinical trials, rising demand for biomarker-based testing, stringent regulatory requirements, and growing adoption of decentralized trials. Moreover, technological advancements such as AI-driven analytics, automation, and digital lab management systems further enhance efficiency, reduce turnaround times, and improve overall trial outcomes.

The market is expanding rapidly due to the increasing number of drug development programs and growing investments in research and development. Pharmaceutical and biotechnology companies are conducting more clinical trials to bring innovative therapies to market, further driving the demand for specialized laboratory services. Biomarker-based testing, genomic analysis, and pharmacokinetics studies are becoming essential for clinical trials, requiring advanced lab capabilities. Regulatory authorities are imposing stringent guidelines for drug approval, making centralized laboratory services critical for ensuring compliance, data accuracy, and standardized testing procedures.

Furthermore, the shift toward decentralized and virtual trials further transforms the industry, increasing the need for efficient sample collection, real-time data integration, and remote testing solutions. Emerging technologies such as AI-driven analytics, automation, and digital lab management systems enhance operational efficiency and accelerate trial timelines. Moreover, strategic collaborations between pharmaceutical companies, CROs, and central lab providers strengthen laboratory networks and expand global testing capabilities. The growing focus on personalized medicine and precision therapies continues to fuel demand for high-quality laboratory services, accelerating the industry's significant growth.

Key market players are adopting various strategies to strengthen their market position. These include strategic partnerships, mergers and acquisitions, and expanding laboratory networks to enhance global reach. Companies also invest in advanced technologies such as AI-driven analytics, automation, and biomarker-based testing to improve efficiency and accuracy. For instance, in February 2025, LabConnect entered into a partnership agreement with SapiSciences to implement a Laboratory Information Management System (LIMS). This collaboration aims to further digitally transform complex research workflows, streamlining sample tracking and enhancing data management within LabConnect's operations.

Clinical Trial Central Laboratory Services Market Report Highlights

Based on service, biomarker testing services dominated the market due to genomic and molecular testing advancements. Regulatory agencies are also encouraging biomarker-based drug approvals, further fueling the market expansion.

Based on the phase, Phase III held the largest market share in 2024 due to the high volume of samples and extensive testing requirements. The growing number of late-stage trials and regulatory mandates further drive demand for central lab services.

Based on Indication, frozen held the largest market share in 2024 due to the rising prevalence of cancer and increasing clinical trials for novel therapies. The growing focus on personalized medicine and biomarker-based diagnostics has amplified the demand for specialized laboratory testing.

Based on end use, pharmaceutical & biopharmaceutical companies held

the largest market share in 2024 due to their high R&D investments and extensive clinical trial pipelines. The increasing demand for specialized testing, biomarker analysis, and precision medicine further strengthened their reliance on central labs

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
 - 1.1.1. Regional Scope
 - 1.1.2. Estimates and Forecast Timeline
- 1.2. Market Definitions
- 1.3. Research Methodology
 - 1.3.1. Information Procurement
 - 1.3.2. Purchased Database
 - 1.3.3. GVR's Internal Database
 - 1.3.4. Secondary Sources
 - 1.3.5. Primary Research
- 1.4. Information or Data Analysis
 - 1.4.1. Data Analysis Models
- 1.5. Market Formulation & Validation
 - 1.5.1. Region Wise Market: Base Estimates
 - 1.5.2. Global Market: CAGR Calculation
- 1.6. Model Details
 - 1.6.1. Commodity Flow Analysis (Model 1)
 - 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
 - 1.6.3. QFD Model Sizing & Forecasting (Model 3)
 - 1.6.4. Bottom-Up Approach (Model 4)
- 1.7. List of Secondary Sources
- 1.8. List of Abbreviations
- 1.9. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent Market Outlook
 - 3.1.2. Related/Ancillary Market Outlook

- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
 - 3.3.1. Market Driver Analysis
 - 3.3.2. Market Restraint Analysis
- 3.4. Technological Advancements
 - 3.4.1. Integration of AI and Digital Technologies
- 3.5. Pricing Model Analysis
- 3.6. Clinical Trials Volume Analysis, 2024
 - 3.6.1. Total Number of Clinical Trials, by Region (2024)
 - 3.6.2. Total Number of Clinical Trials, by Phase (2024)
 - 3.6.3. Total Number of Clinical Trials, by Study Design (2024)
 - 3.6.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
- 3.7. Industry Analysis Tools
 - 3.7.1. Porter's Five Forces Analysis
 - 3.7.2. PESTEL Analysis
 - 3.7.3. COVID-19 Impact Analysis

CHAPTER 4. CLINICAL TRIAL CENTRAL LABORATORY SERVICES MARKET: SERVICE ESTIMATES & TREND ANALYSIS

- 4.1. Segment Dashboard
- 4.2. Clinical Trial Central Laboratory Services Market; Service Movement Analysis
- 4.3. Clinical Trial Central Laboratory Services Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
- 4.4. Biomarker Testing Services
 - 4.4.1. Biomarker testing services market estimates and forecasts 2018 - 2030 (USD Million)
- 4.5. Microbiology Services
 - 4.5.1. Microbiology services market estimates and forecasts 2018 - 2030 (USD Million)
- 4.6. Anatomic Pathology/Histology
 - 4.6.1. Anatomic pathology/histology market estimates and forecasts 2018 - 2030 (USD Million)
- 4.7. Pharmacokinetics/Pharmacodynamics (PK/PD)
 - 4.7.1. Pharmacokinetics/Pharmacodynamics (PK/PD) market estimates and forecasts 2018 - 2030 (USD Million)
- 4.8. Genomic and Molecular Testing
 - 4.8.1. Genomic and molecular testing market estimates and forecasts 2018 - 2030 (USD Million)
- 4.9. Sample Collection and Processing

4.9.1. Sample collection and processing market estimates and forecasts 2018 - 2030 (USD Million)

4.10. Logistics & Sample Management

4.10.1. Logistics & sample management market estimates and forecasts 2018 - 2030 (USD Million)

4.11. Data Management & Reporting

4.11.1. Data management & reporting market estimates and forecasts 2018 - 2030 (USD Million)

4.12. Others

4.12.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

CHAPTER 5. CLINICAL TRIAL CENTRAL LABORATORY SERVICES MARKET: PHASE ESTIMATES & TREND ANALYSIS

5.1. Segment Dashboard

5.2. Clinical Trial Central Laboratory Services Market; Phase Movement Analysis

5.3. Clinical Trial Central Laboratory Services Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)

5.4. Phase I

5.4.1. Phase I market estimates and forecasts 2018 - 2030 (USD Million)

5.5. Phase II

5.5.1. Phase II market estimates and forecasts 2018 - 2030 (USD Million)

5.6. Phase III

5.6.1. Phase III market estimates and forecasts 2018 - 2030 (USD Million)

5.7. Phase IV

5.7.1. Phase IV market estimates and forecasts 2018 - 2030 (USD Million)

CHAPTER 6. CLINICAL TRIAL CENTRAL LABORATORY SERVICES MARKET: INDICATION ESTIMATES & TREND ANALYSIS

6.1. Segment Dashboard

6.2. Clinical Trial Central Laboratory Services Market; Indication Movement Analysis

6.3. Clinical Trial Central Laboratory Services Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)

6.4. Oncology

6.4.1. Oncology market estimates and forecasts 2018 - 2030 (USD Million)

6.5. Cardiology

6.5.1. Cardiology market estimates and forecasts 2018 - 2030 (USD Million)

6.6. Neurology

- 6.6.1. Neurology market estimates and forecasts 2018 - 2030 (USD Million)
- 6.7. Infectious Diseases
 - 6.7.1. Infectious Diseases market estimates and forecasts 2018 - 2030 (USD Million)
- 6.8. Immunology & Autoimmune Diseases
 - 6.8.1. Immunology & autoimmune diseases market estimates and forecasts 2018 - 2030 (USD Million)
- 6.9. Others
 - 6.9.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

CHAPTER 7. CLINICAL TRIAL CENTRAL LABORATORY SERVICES MARKET: END USE ESTIMATES & TREND ANALYSIS

- 7.1. Segment Dashboard
- 7.2. Clinical Trial Central Laboratory Services Market; End Use Movement Analysis
- 7.3. Clinical Trial Central Laboratory Services Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 7.4. Pharmaceutical & Biotechnology Companies
 - 7.4.1. Pharmaceutical & Biotechnology Companies market estimates and forecasts 2018 - 2030 (USD Million)
- 7.5. Contract Research Organizations
 - 7.5.1. Contract Research Organizations market estimates and forecasts 2018 - 2030 (USD Million)
- 7.6. Others
 - 7.6.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

CHAPTER 8. CLINICAL TRIAL CENTRAL LABORATORY SERVICES MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

- 8.1. Regional Dashboard
- 8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
- 8.3. North America
 - 8.3.1. North America clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)
 - 8.3.2. U.S.
 - 8.3.2.1. Key Country Dynamics
 - 8.3.2.2. Competitive Scenario
 - 8.3.2.3. Regulatory Framework
 - 8.3.2.4. U.S. clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.3.3. Canada

8.3.3.1. Key Country Dynamics

8.3.3.2. Competitive Scenario

8.3.3.3. Regulatory Framework

8.3.3.4. Canada clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.3.4. Mexico

8.3.4.1. Key Country Dynamics

8.3.4.2. Competitive Scenario

8.3.4.3. Regulatory Framework

8.3.4.4. Mexico clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.4. Europe

8.4.1. Europe clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.4.2. Germany

8.4.2.1. Key Country Dynamics

8.4.2.2. Competitive Scenario

8.4.2.3. Regulatory Framework

8.4.2.4. Germany clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.4.3. UK

8.4.3.1. Key Country Dynamics

8.4.3.2. Competitive Scenario

8.4.3.3. Regulatory Framework

8.4.3.4. UK clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.4.4. France

8.4.4.1. Key Country Dynamics

8.4.4.2. Competitive Scenario

8.4.4.3. Regulatory Framework

8.4.4.4. France clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.4.5. Italy

8.4.5.1. Key Country Dynamics

8.4.5.2. Competitive Scenario

8.4.5.3. Regulatory Framework

8.4.5.4. Italy clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.4.6. Spain

8.4.6.1. Key Country Dynamics

8.4.6.2. Competitive Scenario

8.4.6.3. Regulatory Framework

8.4.6.4. Spain clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.4.7. Denmark

8.4.7.1. Key Country Dynamics

8.4.7.2. Competitive Scenario

8.4.7.3. Regulatory Framework

8.4.7.4. Denmark clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.4.8. Sweden

8.4.8.1. Key Country Dynamics

8.4.8.2. Competitive Scenario

8.4.8.3. Regulatory Framework

8.4.8.4. Sweden clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.4.9. Norway

8.4.9.1. Key Country Dynamics

8.4.9.2. Competitive Scenario

8.4.9.3. Regulatory Framework

8.4.9.4. Norway clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.5. Asia Pacific

8.5.1. Asia Pacific clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.5.2. Japan

8.5.2.1. Key Country Dynamics

8.5.2.2. Competitive Scenario

8.5.2.3. Regulatory Framework

8.5.2.4. Japan clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.5.3. China

8.5.3.1. Key Country Dynamics

8.5.3.2. Competitive Scenario

8.5.3.3. Regulatory Framework

8.5.3.4. China clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.5.4. India

8.5.4.1. Key Country Dynamics

8.5.4.2. Competitive Scenario

8.5.4.3. Regulatory Framework

8.5.4.4. India clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.5.5. South Korea

8.5.5.1. Key Country Dynamics

8.5.5.2. Competitive Scenario

8.5.5.3. Regulatory Framework

8.5.5.4. South Korea clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.5.6. Australia

8.5.6.1. Key Country Dynamics

8.5.6.2. Competitive Scenario

8.5.6.3. Regulatory Framework

8.5.6.4. Australia clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.5.7. Thailand

8.5.7.1. Key Country Dynamics

8.5.7.2. Competitive Scenario

8.5.7.3. Regulatory Framework

8.5.7.4. Thailand clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.6. Latin America

8.6.1. Latin America clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.6.2. Brazil

8.6.2.1. Key Country Dynamics

8.6.2.2. Competitive Scenario

8.6.2.3. Regulatory Framework

8.6.2.4. Brazil clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.6.3. Argentina

8.6.3.1. Key Country Dynamics

8.6.3.2. Competitive Scenario

8.6.3.3. Regulatory Framework

8.6.3.4. Argentina clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.7. MEA

8.7.1. MEA clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.7.2. South Africa

8.7.2.1. Key Country Dynamics

8.7.2.2. Competitive Scenario

8.7.2.3. Regulatory Framework

8.7.2.4. South Africa clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.7.3. Saudi Arabia

8.7.3.1. Key Country Dynamics

8.7.3.2. Competitive Scenario

8.7.3.3. Regulatory Framework

8.7.3.4. Saudi Arabia clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.7.4. UAE

8.7.4.1. Key Country Dynamics

8.7.4.2. Competitive Scenario

8.7.4.3. Regulatory Framework

8.7.4.4. UAE clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

8.7.5. Kuwait

8.7.5.1. Key Country Dynamics

8.7.5.2. Competitive Scenario

8.7.5.3. Regulatory Framework

8.7.5.4. Kuwait clinical trial central laboratory services market estimates and forecasts, 2018 - 2030 (USD Million)

CHAPTER 9. COMPETITIVE LANDSCAPE

9.1. Company Categorization

9.2. Company Market Position Analysis, 2024

9.3. Company Profiles

9.3.1. Labcorp

9.3.1.1. Company overview

9.3.1.2. Financial performance

9.3.1.3. Service benchmarking

9.3.1.4. Strategic initiatives

9.3.2. ICON plc

- 9.3.2.1. Company overview
- 9.3.2.2. Financial performance
- 9.3.2.3. Service benchmarking
- 9.3.2.4. Strategic initiatives
- 9.3.3. Eurofins Scientific
 - 9.3.3.1. Company overview
 - 9.3.3.2. Financial performance
 - 9.3.3.3. Service benchmarking
 - 9.3.3.4. Strategic initiatives
- 9.3.4. Thermo Fisher Scientific Inc.
 - 9.3.4.1. Company overview
 - 9.3.4.2. Financial performance
 - 9.3.4.3. Service benchmarking
 - 9.3.4.4. Strategic initiatives
- 9.3.5. Medpace
 - 9.3.5.1. Company overview
 - 9.3.5.2. Financial performance
 - 9.3.5.3. Service benchmarking
 - 9.3.5.4. Strategic initiatives
- 9.3.6. Q? Solutions
 - 9.3.6.1. Company overview
 - 9.3.6.2. Financial performance
 - 9.3.6.3. Service benchmarking
 - 9.3.6.4. Strategic initiatives
- 9.3.7. Syneos Health
 - 9.3.7.1. Company overview
 - 9.3.7.2. Financial performance
 - 9.3.7.3. Service benchmarking
 - 9.3.7.4. Strategic initiatives
- 9.3.8. Charles River Laboratories
 - 9.3.8.1. Company overview
 - 9.3.8.2. Financial performance
 - 9.3.8.3. Service benchmarking
 - 9.3.8.4. Strategic initiatives
- 9.3.9. SGS
 - 9.3.9.1. Company overview
 - 9.3.9.2. Financial performance
 - 9.3.9.3. Service benchmarking
 - 9.3.9.4. Strategic initiatives

9.3.10. LabConnect

9.3.10.1. Company overview

9.3.10.2. Financial performance

9.3.10.3. Service benchmarking

9.3.10.4. Strategic initiatives

I would like to order

Product name: Clinical Trial Central Laboratory Services Market Size, Share & Trends Analysis Report
By Phase (Phase I, Phase II, Phase III, Phase IV), By Service, By Indication, By End-use,
By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/CE730A8255E2EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/CE730A8255E2EN.html>